Drug Study
Drug Study
Drug Study
c
c
c
c
c
c
c
c
c
c
c
c
c
c
OPIOID NALBUPHINE 1. RELIEF OF 1. CONTRAINDICA
DIZZINESS, 1. REASSESS
NALBUPHINE ANALGESIC, ACTS AS AN MODERATE TIONS: HEADACHE, PATIENT¶S LEVEL
HYDROCHLORIDE NARCOTIC AGONIST AT TO SEVERE HYPERSENSITIVIT SEDATION OF PAIN AT
AGONIST- SPECIFIC PAIN Y TO LEAST 15 AND 30
ANTAGONIST OPIOID 2. PREOPERAT NALBUPHINE, BRADYCARDIA, MINUTES AFTER
c ANALGESIC RECEPTORS IN IVE SULFITES; HPN, PARENTERAL
NUBAIN THE CNS TO ANALGESIA, LACTATION. HYPOTENSION, ADMINISTRATION
c PRODUCE AS A 2. USE TACHYCARDIA 2. DRUG CAUSES
c
ANALGESIA, SUPPLEMENT CAUTIOUSLY
BLURRED RESPIRATORY
SEDATION BUT TO SURGICAL WITH VISION, DRY DEPRESSION,
ALSO ACTS TO ANESTHESIA, EMOTIONALLY MOUTH WHICH AT 10MG
INJECTION ± 10 CAUSE AND FOR UNSTABLE BILIARY TRACT IS EQUAL TO
MG/ML, 20MG/ML HALLUCINATIO OBSTETRIC CLIENTS OR SPASMS, RESPIRATORY
c
USUAL NS AND IS AN ANALGESIA THOSE WITH A CONSTIPATION DEPRESSION
DOSE IS 10 ANTAGONIST DURING HISTORY OF URINARY PRODUCED BY
MG/70KG, SC, IM AT µ LABOR AND NARCOTIC URGENCY 10MG OF
OR IV Q 3-6H AS RECEPTORS DELIVERY. ABUSE;
MORPHINE
NECESSARY. PREGNANCY RESPIRATORY
INDIVIDUALIZE PRIOR TO LABOR, DEPRESSION
DOSAGE. IN LABOR OR
NONTOLERANT DELIVERY,
PATIENTS, THE BRONCHIAL
RECOMMENDED ASTHMA, COPD,
SINGLE MAXIMUM RESPIRATORY
DOSE IS 20MG, DEPRESSION,
WITH A MAXIMUM ANOXIA,
TOTAL DAILY DOSE INCREASED
OF 160MG. INTRACRANIAL
PATIENTS PRESSURE,
DEPENDENT ON ACUTE MI WHEN
NARCOTICS MAY NAUSEA AND
EXPERIENCE VOMITING ARE
WITHDRAWAL PRESENT,
SYMPTOMS. BILIARY TRACT
SURGERY.
c
NOT
RECOMMENDED
GERIATRIC
PATIENTS OR
PATIENTS WITH
RENAL OR
HEPATIC
IMPAIRMENT:
REDUCE DOSAGE
c
c
c
c
c
ANALGESICS, H2 UNKNOWN. A MODERATE TO 1. CONTRAINDICAT
c
1. MONITOR CV
TRAMADOL RECEPTOR CENTRALLY MODERATELY ED IN PT.'S
DIZZINESS, AND
HYDROCHLORIDE ANTAGONIST ACTING SEVERE PAIN HYPERSENSITIVE VERTILIGO,SOMN RESPIRATORY
SYNTHETIC TO DRUG OR OLENCE,CNS STATUS.
ANALGESIC OTHER OPIOIDS, STIMULATION, WITHHOLD DOSE
c
c COMPOUND BREASTFEEDING ASTHENIA,ANXIET AND NOTIFY
ULTRAM c
NOT WOMEN, Y,DISTURBANCES, PRESCRIBER IF
CHEMICALLY ACUTE EUPHORIA, RESPIRATIONS
300 MG AT RELATED TO INTOXICATION NERVOUSNESS, DECREASE OR
BEDTIME OR 150 OPIOIDS.THOU FROM ALCOHOL, SLEEP RATE IS BELOW
MG TWICE DAILY GHT TO BIND HYPNOTICS, DISORDER,MALAIS 12BPM.
FOR 4-8 WK TO OPIATE CENTRALLY E 2. CAUTION
DEPENDING ON RECEPTORS ACTING AMBULATORY PT
THE CONDITION AND INHIBIT ANALGESICS, TO BE CAREFUL
REUPTAKE OF OPIOIDS OR VASODILATION WHEN RISING AND
NOREPINEPHR PSYCHOTROPIC WALKING.
INE AND DRUGS. NAUSEA, 3. WARN PT. NOT
SEROTONIN. CONSTIPATION, TO STOP DRUG
VOMITING,DRY ABRUPTLY.
MOUTH,DIARRHEA 4. MONITOR PT.'S
AT RISK FOR
c
SEIZURES. DRUG
MAY REDUCE
1. SEIZURES SEIZURE
2. RESPIRATORY THRESHOLD.
DEPRESSION 5. FOR BETTER
ANALGESIC
EFFECT, GIVE
DRUG BEFORE
ONSET OF
INTENSE PAIN.
6. HAVE
EMERGENCY
RESPIRATORY
SUPPORT
EQUIPMENT.(
ENDOTRACHEAL
EQUIPMENT,
VENTILATOR,
OXYGEN,
ATROPINE AND
EPINEPHRINE
c
c
c
c
c
CNS AGENT; ALTERS RELIEF OF HYPERSENSITIVITY 1. LIGHTHEADEDN 1. CAUTION
MORPHINE NARCOTIC PERCEPTION MODERATE TO TO OPIATES; ESS PATIENT NOT TO
SULFATE (OPIATE) AGONIST AND SEVERE PAIN INCREASED 2. DIZZINESS CHEW OR CRUSH
EMOTIONAL NOT INTRACRANIAL 3. SEDATION CONTROLLED-
c
c RESPONSE TO RESPONSIVE PRESSURE; 4. NAUSEA RELEASE
c
PAIN TO NON- CONVULSIVE 5. VOMITING PREPARATIONS.
c
: 5-20 MG NARCOTIC DISORDERS 6. CONSTIPATION 2. DILUTE AND
IM/SC 4 HOURLY. ANALGESICS. 7. SWEATING. ADMINISTER
SEVERE OR PREMED. SLOWLY IV TO
CHRONIC PAIN ANALGESIC MINIMIZE
c 10 MG ADJUNCT IN LIKELIHOOD OF
IM/SC 4 HOURLY, GENERAL ADVERSE
RANGE: 5-20 MG; 6- ANESTHESIA EFFECTS.
12 YR 5-10 MG, 1-5 ESPECIALLY IN 3. TELL PATIENT
YR 2.5-5 MG, 1-12 PAIN TO LIE DOWN
MONTH 200 ASSOCIATED DURING IV
MCG/KG, <1 MONTH W/ CANCER, MI ADMINISTRATION.
150 MCG/KG 4 & SURGERY. 4. KEEP OPIOID
HOURLY. MAX: 15 ALLEVIATES ANTAGONIST AND
MG. ANALGESIC ANXIETY FACILITIES FOR
EFFECT ASSOCIATED ASSISTED OR
c
100-200 W/ SEVERE CONTROLLED
MCG/KG SC 4 PAIN. RESPIRATION
HOURLY, MAX: 15 HYPNOTIC FOR READILY
MG/DOSE; OR 50- PAIN-RELATED AVAILABLE
100 MCG/KG SLOW SLEEPLESSNES DURING IV
IV. PRE-OP 50-100 S. ADMINISTRATION.
MCG/KG IM, MAX: 5. USE CAUTION
10 MG/DOSE. WHEN INJECTING
SC OR IM INTO
CHILLED AREAS
OR IN PATIENTS
WITH
HYPOTENSION OR
IN SHOCK;
IMPAIRED
PERFUSION MAY
DELAY
ABSORPTION.
6. REASSURE
PATIENTS THAT
THEY ARE
UNLIKELY TO
BECOME
ADDICTED.
c
c
c
c
c
CNS AGENT; BINDS WITH RELIEF OF HYPERSENSITIVITY 1. CIRCULATOR 1. MAKE POSITION
MEPERIDINE NARCOTIC OPIATE MODERATE TO TO MEPERIDINE, Y DEPRESSION CHANGES SLOWLY
HYDROCHLORIDE (OPIATE) AGONIST RECEPTORS IN SEVERE PAIN, CONVULSIVE 2. SHOCK AND IN STAGES
ANALGESIC; THE CNS, PRE-OP DISORDERS; 3. CARDIAC PARTICULARLY
c ANTI-VERTIGO ALTERING MEDICATION, ACUTE ABDOMINAL ARREST FROM RECUMBENT
DEMEROL DRUG PERCEPTION SUPPORT OF CONDITIONS PRIOR 4. GI TO UPRIGHT
OF AND ANESTHESIA & TO DIAGNOSIS; DISTURBANCE POSTURE.
c EMOTIONAL OBSTETRICIAN PREGNANCY PRIOR 5. LIGHT 2. LIE DOWN
c
RESPONSE TO ANALGESIA TO LABOR HEADEDNESS WHEN FEELING
100 MG/ 2ML PAIN DIZZINESS NAUSEATED AND
6. SEDATION TO NOTIFY
7. NAUSEA PHYSICIAN IF THIS
8. VOMITING SYMPTOM
9. SWEATING PERSISTS. AVOID
10. WEAKNESS DRIVING AND
11. HEADACHE OTHER
12. TREMOR POTENTIALLY
13. SEVERE HAZARDOUS
CONVULSIONS ACTIVITIES UNTIL
VISUAL REACTION TO
DISTURBANCE DRUG IS KNOWN.
14. TACHYCARDI 3. DO NOT TAKE
A BRADYCARDIA ALCOHOL OR
15. PALPITATION OTHER CNS
HYPOTENSION DEPRESSANTS
SYNCOPE UNLESS
16. PHLEBITIS APPROVED BY
17. URINARY PHYSICIAN.
RETENTION 4. HYPERACTIVE
ALLERGIC COUGH MAY BE
REACTIONS, LESSENED BY
PAIN AT AVOIDING
INJECTION SITE IRRITANTS SUCH
AND LOCAL AS SMOKING,
TISSUE DUST, FUMES AND
IRRITATION. OTHER AIR
POLLUTANTS.
DO NOT
BREAST FEED
WHILE TAKING
THIS DRUG.
c
c
c
c
c
ANTICONVULSANT; MAY TREATMENT OF MYOCARDIAL FLUSHING, MONITOR THE
MAGNESIUM GASTROINTESTINA DECREASE HYPOMAGNESE DAMAGE; HEART SWEATING, FOLLOWING: I.V.:
SULFATE L AGENT ACETYLCHOLI MIA BLOCK; CARDIAC HYPOTENSION, RAPID
NE RELEASED ACCOMPANIED ARREST EXCEPT MUSCULAR ADMINISTRATION:
c
c BY NERVE BY SIGNS OF FOR CERTAIN WEAKNESS, ECG MONITORING,
EPSOM SALT c
IMPULSES, TETANY, ARRHYTHMIAS; IV SEDATION & VITAL SIGNS, DEEP
250 MG/10 ML BUT ITS CONTROL OF ADMINISTRATION CONFUSION; TENDON
ANTICONVULS HTN, DURING THE DECREASED DEEP REFLEXES;
ANT ENCEPHALOPH 2HOURS TENDON MAGNESIUM,
MECHANISM IS ATHY & PRECEDING REFLEXES; RESP. CALCIUM, AND
UNKNOWN CONVULSIONS, DELIVERY. PARALYSIS POTASSIUM
PREVENTION & LEVELS; RENAL
CONTROL OF FUNCTION DURING
CONVULSIONS ADMINISTRATION.
IN PATIENTS W/ OBSTETRICS:
PREECLAMPSIA PATIENT STATUS
OR ECLAMPSIA, INCLUDING VITAL
PREVENTION SIGNS, OXYGEN
OF SATURATION,
HYPOMAGNESE DEEP TENDON
MIA IN REFLEXES, LEVEL
PATIENTS OF
RECEIVING TPN CONSCIOUSNESS,
FETAL HEART
RATE, MATERNAL
UTERINE ACTIVITY.
ORAL: RENAL
FUNCTION;
MAGNESIUM
LEVELS; BOWEL
MOVEMENTS.
c
c
c
c
c
CORTICOSTEROID; DECREASES ENDOCRINE, HYPERSENSITIVITY 1. 1. GIVE DAILY
HYDROCORTISONE SYNTHETIC INFLAMMATION, HEMATOLOGIC, TO
BEFORE 9 AM TO
SODIUM HORMONES MAINLY BY RHEUMATIC & GLUCOCORTICOID
MIMIC NORMAL
SUCCINATE STABILIZING COLLAGEN S, IDIOPATHIC 2.
PEAK DIURNAL
c LEUKOCYTE DISORDERS, THROMBOCYTOPE CORTICOSTEROID
c c
LYSOSOMAL DERMATOLOGI NIC PURPURA,
LEVELS AND
A-HYDROCORT, j
MEMBRANES, C, PSYCHOSES, 3.
MINIMIZE HPA
SOLU-CORTEF
SUPPRESSES OPHTHALMOLO ACUTE SUPPRESSION.
IMMUNE GY, GI, GLOMERULONEPH
2. DO NOT GIVE
RESPONSE, RESPIRATORY RITIS, VIRAL OR IM INJECTIONS IF
4.
STIMULATES & NEOPLASTIC BACTERIAL PATIENT HAS
BONE MARROW DISEASES, DISEASES OF SKIN, THROMBO-
AND EDEMATOUS INFECTIONS NOT 5.
CYTOPENIC
INFLUENCES STATES, CONTROLLED BY
PURPURA.
PROTEIN, FAT, CONTROL OF ANTIBIOTICS 6.
3. ROTATE SITES
AND SEVERE OF IM
CARBOHYDRAT INCAPACITATIN 7.
REPOSITORY
E METABOLISM G ALLERGIC
INJECTIONS TO
CONDITIONS, 8.
AVOID LOCAL
TB MENINGITIS
ATROPHY.
W/
4. USE MINIMAL
SUBARACHNOI
DOSES FOR
D BLOCK OR 9. MINIMAL
IMPENDING 10.
DURATION TO
BLOCK WHEN MINIMIZE
USED ADVERSE
CONCURRENTL EFFECTS.
Y WITH
5. ARRANGE FOR
APPROPRIATE 11.
INCREASED
ANTI-TB
DOSAGE WHEN
CHEMOTHERAP PATIENT IS
12.
Y, SHOCK SUBJECT TO
SECONDARY UNUSUAL STRESS.
TO 6. USE
ADRENOCORTI 13.
ALTERNATE-DAY
CAL 14.
MAINTENANCE
INSUFFICIENCY
THERAPY WITH
OR SHOCK SHORT-ACTING
UNRESPONSIV CORTICOSTEROID
E TO S WHENEVER
CONVENTIONAL POSSIBLE.
THERAPY 7. DO NOT GIVE
WHEN LIVE VIRUS
ADRENOCORTI VACCINES WITH
CAL IMMUNOSUPPRES
INSUFFICIENCY SIVE DOSES OF
MAY BE HYDROCORTISON
PRESENT E.
PROVIDE
ANTACIDS
BETWEEN MEALS
TO HELP AVOID
PEPTIC ULCER.
c
c
c
c
c
FLUID AND REPLACES HYPOCALCEMI VENTRICULAR 1. GI IRRITATION 1. MAKE SURE
CALCIUM ELECTROLYTIC CALCIUM AND A, HYPERMAG- FIBRILLATION, 2. SOFT-TISSUE PRESCRIBER
GLUCONATE AND WATER MAINTAINS NESEMIA, METASTATIC BONE CALCIFICATION SPECIFIES FORM
AGENT; CALCIUM LEVEL HYPERKALEMIA DISEASE, 3. SKIN OF CALCIUM TO BE
c REPLACEMENT INJECTION INTO SLOUGHING OR GIVEN; CRASH
KALCINATE SOLUTION MYOCARDIUM, NECROSIS AFTER CARTS MAY
PREGNANCY IM/SC INJ. CONTAIN BOTH
c 4. HYPERCALCE CALCIUM
c
MIA GLUCONATE AND
CHARACTERIZED CALCIUM
HYPOCALCEMIA 10- BY CHLORIDE.
50 MMOL/DAY. è ANOREXIA 2. TELL PATIENT
HYPOCALCEMIC è NAUSEA TO TAKE ORAL
TETANY 2.25 MMOL è VOMITING CALCIUM 1 TO 11/2
VIA SLOW è CONSTIPA HOURS AFTER
INJECTION , THEN TION MEALS IF GI UPSET
58-77 ML OF 10% è ABDOMINA OCCURS.
SOLUTION DILUTED L PAIN 3. GIVE I.M.
AND è MUSCLE INJECTION IN
ADMINISTERED AS WEAKNESS GLUTEAL REGION
A CONTINUOUS IV è MENTAL IN ADULTS AND IN
INFUSION. DISTURBA LATERAL THIGH IN
ANTIDOTE IN NCES INFANTS. USE I.M.
SEVERE ROUTE ONLY IN
è POLYDIPSI
HYPERMAGNESEMI EMERGENCIES
A
A; SEVERE WHEN NO I.V.
è POLYURIA
HYPERKALEMIA 10 ROUTE IS
ML OF 10% è NEPHROCA AVAILABLE
SOLUTION, REPEAT L-CINOSIS BECAUSE OF
EVERY 10 MINUTES è RENAL IRRITATION OF
IF NEEDED. CALCULI TISSUE BY
è CHALKY CALCIUM SALTS.
TASTE 4. TELL PATIENT
è HOT TO TAKE ORAL
FLUSHES CALCIUM WITH A
è PERIPHER FULL GLASS OF
AL WATER.
VASODILAT 5. MONITOR
ION. CALCIUM LEVELS
5. POTENTIALLY FREQUENTLY.
FATAL: CARDIAC HYPERCALCEMIA
ARRHYTHMIAS MAY RESULT
AND COMA. AFTER LARGE
DOSES IN
CHRONIC RENAL
FAILURE. REPORT
ABNORMALITIES.
c
c
c
c
c
ANTACID NEUTRALIZES SYMPTOMATIC PROLONGED USE 1. GI: 1. IT SHOULD BE
ALUMINUM GASTRIC RELIEF OF OF HIGH DOSES IN è CONSTIPA- TAKEN 1 HOUR
HYDROXIDE/
c ACIDITY THUS HYPERACIDITY. PRESENCE OF TION AFTER MEAL.
MAGNESIUM c
REDUCES THE LOW SERUM è DIARRHEA 2. ASSESS
HYDROXIDE 200MG/200MG 1 TOTAL ACID PHOSPHATE, è STOMACH PATIENT¶S
TAB PO, BID LOAD OF THE PREGNANCY CRAMPS DISCOMFORT
GI TRACT. è FECAL BEFORE
c STRENGTHENS IMPACTION THERAPY.
MAALOX GASTRIC è NAUSEA 3. MONITOR
MUCOSAL è VOMITING PHOSPHATE
BARRIER AND LEVELS
INCREASES 2. REFER TO HYPOPHOSPHATE
ESOPHAGEAL PHYSICIAN: MIA: ANOREXIA,
SPHINCTER HYPOMAGNESEMI WEAKNESS
TONE. A FATIGUE AND
BONE PAIN.
c
c
c
c
c
NOOTROPIC AND CITICHOLINE CEREBROVASC HYPERSENSITIVITY 1. STOMACH 1. WATCH OUT
CITICHOLINE NEUROTONIC ACTIVATES ULAR REACTION PAIN FOR
THE DISEASES, PARASYMPATHETIC 2. DIARRHEA HYPOTENSIVE
c
c BIOSYNTHESIS ACCELERATES HYPERTONIA. 3. TACHYCARDIA EFFECT
ZYNAPSE c
OF THE RECOVERY 4. BRADYCARDIA 2. MONITOR
500MG IV Q8 STRUCTURAL OF 5. FLEETING AND PATIENTS
PHOSPHOLIPID CONSCIOUSNE DISCRETE NEUROLOGIC
S IN THE SS AND HYPOTENSION STATUS
NEURONAL OVERCOMING EFFECT 3. NOTE IF THERE
MEMBRANE, MOTOR 6. INCREASED ARE SIGNS OF
INCREASES DEFICIT. PARASYMPATHET SLURRING OF
CEREBRAL IC AFFECTS SPEECH
METABOLISM 7. LOW BLOOD 4. NOTE FOR
AND PRESSURE ADVERSE
INCREASES 8. ITCHING OR REACTIONS
THE LEVEL OF HIVES 5. TITER
VARIOUS 9. SWELLING IN MEDICATION
NEUROTRANS FACE OR HANDS WHEN
MITTERS, 10. CHEST DISCONTINUING
INCLUDING TIGHTNESS
ACETYLCHOLI 11. TINGLING
NE AND IN MOUTH AND
DOPAMINE. THROAT
CITICOLINE
HAS SHOWN
NEUROPROTE
CTIVE
EFFECTS IN
SITUATIONS
OF HYPOXIA
AND ISCHEMIA.
c
c
c
c
c
GIT REGULATORS, METOCLOPRAM DISTURBANCES SENSITIVITY OR 1. RESTLESSNES 1. GIVE 30 MINS
METOCLOPRAMIDE ANTI-FLATULENTS, IDE, A OF GI MOTILITY INTOLERANCE TO S DROWSINESS BEFORE MEALS
ANTI- DOPAMINE INCLUDING GE METOCLOPRAMIDE; 2. FATIGUE AND AT BED TIME
c INFAMMATORY ANTAGONIST, RD & DIABETIC ALLERGY TO 3. LASSITUDE
PLASIL STIMULATES GASTROPARESI SULFATING 4. EXTRAPYRAMI 2. ASSESS
c MOTILITY OF S. NAUSEA &VO AGENTS; HISTORY DAL SYMPTOMS MENTAL STATUS
c
THE UPPER MITING OF OF SEIZURE 5. INSOMNIA DURING
÷ GASTROINTEST CENTRAL & DISORDERS; 6. HEADACHE TREATMENT
÷ 1 TAB TID. INAL TRACT PERIPHERAL CONCURRENT USE 7. DIZZINESS
V WITHOUT ORIGIN OF DRUGS THAT 8. NAUSEA 3. TELL PATIENT
° 2.5-5 MG STIMULATING ASSOCIATED CAN CAUSE 9. GALACTORRH TO AVOID DRIVING
TID, GASTRIC, W/ SURGERY, EXTRAPYRAMIDAL EA & OTHER
° 2 MG BID- BILIARY OR METABOLIC SYMPTOMS 10. GYNECOMAS HAZARDOUS
TID, PANCREATIC DISEASES, TIA, ACTIVITIES FOR
1 MG BID- SECRETIONS. INFECTIOUS 11. RASH AT LEAST 2 HRS
TID, ITS MODE OF DISEASES, MIG INCLUDING
1 MG BID. ACTION IS RAINE HEADAC URTICARIA, 4. ADVICE PT. TO
MAX: 0.5 UNCLEAR. IT HE OR DRUGS BOWEL AVOID ALCOHOL
MG/KG/DAY. SEEMS TO INCLUDING DISTURBANCES. AND OTHER CNS
Y 10 ML SENSITIZE CANCER 12. INCREASED DEPRESSANT
TID. TISSUES TO CHEMOTHERAP PROLACTIN THAT ENHANCE
Y 1 THE ACTION OF Y. FACILITATE LEVELS; SEDATING
AMP 8 HOURLY. ACETYLCHOLIN SMALL BOWEL GASTROPARESIS. PROPERTIES OF
RADIOLOGICAL E. THE EFFECT INTUBATION & THIS DRUG
EXAM OF GIT 1-2 OF RADIOLOGICAL
AMP IM OR IV 10 METOCLOPRAM PROCEDURES
MIN BEFORE IDE ON OF GIT
PROCEDURE. MOTILITY IS
Y NOT
Y
DEPENDENT
½ THE ON INTACT
RECOMMENDED VAGAL
DOSE. INNERVATION
BUT IT CAN BE
ABOLISHED BY
ANTICHOLINER
GIC DRUGS.
ASSESSMENT NURSING SCIENTIFIC PLANNING IMPLEMENTATION RATIONALE EVALUATION
DIAGNOSIS KNOWLEDGE
DEPENDENT: FOR POSITION
SUBJECTIVE DATA: IMPAIRED VEHICULAR SHORT TERM GOAL: INSTRUCT THE PATIENT CHANGES OR AFTER 2-3 HOURS
³NAHIHIRPAN AKONG PHYSICAL ACCIDENT IN 2-3 HOURS OF TO USE ASSISTIVE DEVICE TRANSFER. OF NURSING
KUMILOS.´ AS MOBILITY R/T NURSING LIKE SIDERAILS OR INTERVENTIONGO
VERBALIZED BY THE MUSCULOSKELE INJURIES OF INTERVENTIONS THE WHEELCHAIR. ALS TO
PATIENT. TAL IMPAIRMENT FACE AND CLIENT WILL BE ABLE TO MAINTAIN MAINTAINOR
AS EVIDENCED EXTREMITIES TO MAINTAIN OR SUPPORT AFFECTED POSITION INCREASE
OBJECTIVE DATA: BY DECREASE INCREASE STRENGTH BODY PARTS OR JOINT FUNCTION AND STRENGTH AND
SLOWED MOVEMENT MUSCLE INFLAMMATION AND FUNCTION OF USING PILLOW, ROLLS, T REDUCED RISK OF FUNCTION OF
OF BOTH UPPER AND STRENGTH. AFFECTED BODY SUPPORT. PRESSURE ULCER. AFFECTED BODY
LOWER EXTREMITIES. IMPAIRED PARTS AS EVIDENCED PARTS WERE MET
DIFFICULTY TURNING PHYSICAL BY: TO PREVENT THE AS EVIDENCED
LIMITED RANGE OF MOVEMENT. VERBALIZE PROVIDE FOR SAFETY PATIENT FROM BY:
MOTION OF BOTH UNDERSTANDING OF MEASURE INJURY. ABILITY TO MOVE
UPPER AND LOWER SITUATION AND AS INDICATED BY THE AFFECTED
EXTREMITIES. INDIVIDUALTREATMENT INDIVIDUAL SITUATION BODY PARTS
REGIMEN AND SAFETY INCLUDING WITHOUT
MEASURES. ENVIRONMENTAL DISCOMFORT
ABILITY TO MOVE THE MANAGEMENT AND FULL VERBALIZED
AFFECTED BODY PREVENTION. TO MAINTAIN THE UNDERSTANDING
PARTS WITHOUT PATIENT THE SITUATION
DISCOMFORT. PROVIDE REGULAR SKIN INTEGRITY. AND INDIVIDUAL
DEMONSTRATE CARE TO INCLUDE TREATMENT
TECHNIQUE OR PRESSURE AREA REGIMEN AND
BEHAVIORS THAT MANAGEMENT. TO PROMOTE SAFETY
ENABLE RESUMPTION WELL BEING AND MEASURE
OF ACTIVITIES. ENCOURAGED THE MAXIMIZED DEMONSTRATE
LONG TERM GOAL: PATIENT ADEQUATE ENERGY TECHNIQUE OR
AFTER 2-3 WEEKS OF INTAKE OF FLUIDS AND PRODUCTION. BEHAVIORS THAT
NURSING NUTRITIOUS FOOD. ENABLE
INTERVENTION THE TO PROMOTE RESUMPTION OF
PATIENT WILL BE ABLE PROPER ACTIVITIES.
TO IMPROVE PHYSICAL ENCOURAGED THE CIRCULATION OF ABILITY TO
MOBILITY AS PATIENT TO HAVE BLOOD IN THE PERFORMED ROM
EVIDENCED BY: REGULAR EXERCISE. BODY. EXERCISE.
ABILITY TO SCHEDULED ACTIVITIES TO REDUCE
PERFORMED ROM WITH ADEQUATE REST FATIUE.
EXERCISE. PERIOD DURING THE DAY.
PARTICIPATE ADLS
AND DESIRED INDEPENDENT:
ACTIVITY. ASSIST OR HAVE THE TO PROMOTE THE
MAINTAIN POSITION OF PATIENT REPOSITION PATIENT
FUNCTION AND SKIN SELF ON A REGULAR PROGRESS.
INTEGRITY AS SCHEDULED AS DICTATED
EVIDENCED BY BY INDIVIDUAL.
ABSENCE OF
CONTRACTURE, PERFORMED ROM TO PROMOTE
FOOTDROP, EXERCISE AS DOCTOR¶S PATIENT MUSCLE
DECUBITUS. ORDERED. STRENGTH
ABILITY TO WALK THE
PATIENT WITHOUT PERFORMED WARM TO PROMOTE
ASSISTIVE DEVICE. COMPRESS AS DOCTOR¶S HEALING
ORDERED. PROCESS.
!"#$
%&'
()*+,-./ !0"-) ," !!